AB Science Receives U.S. Food and Drug Administration (FDA) Authorization to Initiate Confirmatory Phase III Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science SA announced that it had received an IND approval letter from the FDA to initiate Phase III study in patients with mild to moderate Alzheimer’s disease
[AB Science SA]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News